SCYNEXIS, Inc. (SCYX)
3.785
-0.02
(-0.66%)
USD |
NASDAQ |
Oct 23, 16:00
3.77
-0.02
(-0.40%)
After-Hours: 20:00
SCYNEXIS Net Income (Quarterly) : 7.397M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 7.397M |
| March 31, 2026 | -21.30M |
| December 31, 2025 | 12.26M |
| September 30, 2025 | -8.591M |
| June 30, 2025 | -6.885M |
| March 31, 2025 | -5.391M |
| December 31, 2024 | -4.433M |
| September 30, 2024 | -2.808M |
| June 30, 2024 | -14.46M |
| March 31, 2024 | 0.411M |
| December 31, 2023 | -19.59M |
| September 30, 2023 | -1.757M |
| June 30, 2023 | 122.26M |
| March 31, 2023 | -33.88M |
| December 31, 2022 | -14.43M |
| September 30, 2022 | -29.58M |
| June 30, 2022 | -13.34M |
| March 31, 2022 | -5.451M |
| December 31, 2021 | -29.24M |
| September 30, 2021 | -0.605M |
| June 30, 2021 | 1.658M |
| March 31, 2021 | -4.676M |
| December 31, 2020 | -42.71M |
| September 30, 2020 | 0.909M |
| June 30, 2020 | -6.381M |
| Date | Value |
|---|---|
| March 31, 2020 | -7.002M |
| December 31, 2019 | -14.46M |
| September 30, 2019 | -7.941M |
| June 30, 2019 | -8.403M |
| March 31, 2019 | -22.91M |
| December 31, 2018 | 1.942M |
| September 30, 2018 | 0.351M |
| June 30, 2018 | -10.76M |
| March 31, 2018 | -4.002M |
| December 31, 2017 | -7.59M |
| September 30, 2017 | -8.401M |
| June 30, 2017 | -4.199M |
| March 31, 2017 | -4.869M |
| December 31, 2016 | -3.449M |
| September 30, 2016 | -11.23M |
| June 30, 2016 | -8.128M |
| March 31, 2016 | -7.184M |
| December 31, 2015 | -8.388M |
| September 30, 2015 | -7.529M |
| June 30, 2015 | -6.492M |
| March 31, 2015 | -6.384M |
| December 31, 2014 | -3.075M |
| September 30, 2014 | -3.804M |
| June 30, 2014 | 2.233M |
| March 31, 2014 | -1.221M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 23.00M |
| Corcept Therapeutics, Inc. | 42.14M |
| Veru, Inc. | -6.988M |
| Johnson & Johnson | 210.00M |
| Eli Lilly & Co. | 7.095B |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 0.235M |
| Total Expenses (Quarterly) | -7.162M |
| EPS Diluted (Quarterly) | 0.6256 |
| Enterprise Value | -14.56M |
| Earnings Yield | -48.70% |
| Normalized Earnings Yield | -58.18 |